Stockscreener 앱 받기
14.05
2.87%
-0.385
전일 마감가:
$14.44
열려 있는:
$14.65
하루 거래량:
740.20K
Relative Volume:
0.70
시가총액:
$1.18B
수익:
$7.62M
순이익/손실:
$-271.60M
주가수익비율:
-4.0137
EPS:
-3.5018
순현금흐름:
$-271.54M
1주 성능:
-1.92%
1개월 성능:
+19.06%
6개월 성능:
-19.26%
1년 성능:
+47.79%
1일 변동 폭
$13.74
$14.85
1주일 범위
$13.01
$15.92
52주 변동 폭
$9.40
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
명칭
Eyepoint Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
14.09 | 1.17B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
520.41 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
670.00 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.27 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.90 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Inc 주식(EYPT)의 최신 뉴스
EYPT Rated Buy by Chardan Capital -- Price Target Raised to $65. - GuruFocus
Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating - marketscreener.com
Did Broad Russell Growth Index Additions Just Reframe EyePoint’s (EYPT) Small-Cap Biotech Profile? - simplywall.st
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2500 Growth Benchmark - marketscreener.com
Pivotal Clinical Trial Readouts On The Horizon; Keeping An Eye On EyePoint? - RTTNews
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2000 Growth Benchmark - marketscreener.com
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 3000E Growth Benchmark - marketscreener.com
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
EyePoint, Inc. Actuals & Estimates (NASDAQ:EYPT) - TradingView
Price to book forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
Price to book forward of EyePoint, Inc. – LS:A2QJRU - TradingView
EYPT Forecast — Price Target — Prediction for 2027 - TradingView
EyePoint, Inc. Actuals & Estimates (DUS:PV3B) - TradingView
(EYPT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Price to sales forward of EyePoint, Inc. – LS:A2QJRU - TradingView
EyePoint Inc (EYPT) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Enterprise value to revenue forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
Price to earnings forward of EyePoint, Inc. – LS:A2QJRU - TradingView
A2QJRU Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of EyePoint, Inc. – LS:A2QJRU - TradingView
EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence - TradingKey
Guggenheim Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $68 - Moomoo
EYPT Reiterated by Guggenheim -- Price Target Maintained at $68. - GuruFocus
Mizuho reiterates EyePoint stock rating on competitor timeline shift By Investing.com - Investing.com South Africa
Mizuho reiterates EyePoint stock rating on competitor timeline shift - Investing.com
Mizuho Securities Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
EyePoint stockholders approve incentive plan amendment and elect directors By Investing.com - Investing.com South Africa
EyePoint, Inc. Approves Executive Compensation and Amends 2023 Long-Term Incentive Plan in Latest 8-K Filing - Minichart
Form 8K Eyepoint Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com Nigeria
EyePoint stockholders approve incentive plan amendment and elect directors - Investing.com
EyePoint (EYPT) investors approve 4.9M-share incentive plan increase and all 2026 AGM proposals - Stock Titan
EyePoint Pharmaceuticals Inc (EYPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
JonesTrading Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $43 - Moomoo
EyePoint Pharmaceuticals Inc - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Valuation: PE, PB & Fair Value Analysis - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
(EYPT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
EyePoint Pharmaceuticals Stock (US30233B1098): Analyst views and valuation in focus - AD HOC NEWS
EyePoint Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
EYPT: Phase III retinal drug aims for six-month dosing, rapid vision gains, and commercial readiness - TradingView
EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance - MSN
COMMODORE CAPITAL LP Increases Stake in EyePoint Inc - GuruFocus
Earnings call transcript: Eyepoint Pharmaceuticals misses Q1 2026 EPS and revenue forecasts - Investing.com
(EYPT) Risk Channels and Responsive Allocation - Stock Traders Daily
Eyepoint Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Eyepoint Inc 주식 (EYPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ribeiro Ramiro | Chief Medical Officer |
Jun 30 '26 |
Sale |
15.01 |
4,875 |
73,167 |
0 |
| Elston George | Chief Financial Officer |
May 25 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
95,318 |
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Option Exercise |
8.26 |
2,437 |
20,130 |
2,437 |
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Sale |
15.00 |
2,437 |
36,555 |
0 |
0.82%
0.85%
자본화:
|
볼륨(24시간):